At the Virginia Tech Corporate Research Center (VTCRC), we celebrate the groundbreaking work of our tenants like Iambic Therapeutics . The clinical-stage biotech company, known for its cutting-edge AI-driven drug discovery platform, continues to make waves in the industry.
Iambic’s CEO and Co-Founder, Tom Miller, Ph.D., will present at the 43rd Annual JP Morgan Healthcare Conference on January 14, 2025, in San Francisco. This event will spotlight Iambic’s updates on a promising HER2 inhibitor in Phase 1 trials and developments in their pipeline.
Iambic’s innovative AI platform accelerates the discovery of novel therapeutics by integrating physics principles with advanced machine learning models. This technology allows the company to address complex drug design challenges, positioning Iambic as a leader in next-generation therapeutics.
About
Founded in 2019, Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinical stage with unprecedented speed and across multiple target classes and mechanisms of action. The team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs.
We are proud to have Iambic as part of the VTCRC community, exemplifying the innovation and entrepreneurial spirit that defines our ecosystem. Stay tuned for more updates from Iambic and other trailblazing tenants shaping the future of healthcare.
Learn more here: iambic.ai.